A Randomized, Open-Label Study to Evaluate the Bioavailability of a BMS-986205 Tablet Containing Free Base Relative to a Reference Tablet in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs BMS 986205 (Primary)
- Indications Cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 28 Feb 2018 Status changed from recruiting to completed.
- 17 Jan 2018 Status changed from not yet recruiting to recruiting.
- 27 Dec 2017 New trial record